A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT04025879. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Resection and Adjuvant Treatment With Nivolumab or Placebo for Participants With Resectable Stage II-IIIB Non-small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.
Study identification
- NCT ID
- NCT04025879
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 461 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Biological
- Carboplatin Drug
- Cisplatin Drug
- Paclitaxel Drug
- Pemetrexed Drug
- Placebo Drug
- Docetaxel Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 5, 2019 (Actual)
- Primary completion
- Jul 26, 2023 (Actual)
- Completion
- Jul 31, 2027 (Estimated)
- Last update posted
- Aug 26, 2026
2019 – 2027
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0104 | Tampa | Florida | 33612 | — |
| Local Institution - 0040 | Atlanta | Georgia | 30342 | — |
| Local Institution - 0120 | Augusta | Georgia | 30912 | — |
| Local Institution - 0145 | Chicago | Illinois | 60611 | — |
| Local Institution - 0078 | Chicago | Illinois | 60612 | — |
| Local Institution - 0121 | Orland Park | Illinois | 60462 | — |
| Rcca Md Llc | Bethesda | Maryland | 20817 | — |
| Local Institution - 0076 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0074 | Newton | Massachusetts | 02459 | — |
| Local Institution - 0086 | Traverse City | Michigan | 49684 | — |
| Local Institution - 0100 | Lebanon | New Hampshire | 03756 | — |
| Local Institution - 0055 | Cincinnati | Ohio | 45220 | — |
| Local Institution - 0102 | Cleveland | Ohio | 44106 | — |
| Local Institution - 0054 | Houston | Texas | 77030 | — |
| Local Institution - 0103 | Fredericksburg | Virginia | 22408 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 93 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04025879, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 26, 2026 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04025879 live on ClinicalTrials.gov.